Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Blackstone sells 3,000 UK homes to pensions giant USS in a $519m deal
Private equity giant Blackstone announced on Tuesday it had sold 3,000 shared-ownership homes to Britain's biggest private pension fund, in a sign of growing dealmaking by big money managers in the UK housing sector. Blackstone sold the portfolio to academia pension...
Carlyle strikes $3.8bn deal for Baxter’s kidney care segment
Global investment firm Carlyle has agreed to acquire US medtech company Baxter International’s kidney care segment — to be named Vantive — for $3.8bn, concluding talks initially reported by Reuters and the Wall Street Journal last month. The transaction is expected to...
KKR plans $4bn Fuji Soft take-private deal
US private equity major KKR is planning to take Japanese systems developer Fuji Soft private in a deal valued at around JPY600bn ($4.13bn), according to a report by NikkeiAsia citing unnamed sources familiar with the matter. The move comes amid pressure from Fuji...